Weekly Paclitaxel Therapy as the Second-line Chemotherapy to TS-1 for Advanced/Metastatic Gastric Cancer

摘要

Twenty-one patients with advanced gastric cancer (AGC) resistant for TS-1 therapy underwent weekly Paclitaxel therapy between 2003 and 2004. Paclitaxel was administered at a weekly dose of 70mg/m2/day for three weeks followed by a one week interval unless disease progression or intolerable loxicity was observed. The median number of treatment cycles was four. The median relative dose-intensity was 83.2%. Grade3 or more of non hematological toxicity was not observed. Leukocytopenia, neutropenia and anemia of grade 3 or more were observed in 5%, 33%, and 5% of patients, respectively. The overall response rate was 33.3%. The median time to treatment failure was 127 days. Median survival time (MST) from the start of TS-1 therapy and from the start of weekly Paclitaxel therapy were 674 days and 447 days, respectively. Our data indicated that weekly paclitaxel therapy as the second-line chemotherapy to TS-1 may be feasible for the patients with AGC resistant for TS-1.